Loughborough University has announced a significant milestone for its innovative spin-out company, Myomaker Bio. The company, which is pioneering the use of lab-grown human muscles for drug testing, has secured £325,000 in investment from SFC Capital. This funding will accelerate the development of their groundbreaking technology, which aims to revolutionize the pharmaceutical industry by providing more accurate and ethical methods for testing new drugs.
Revolutionizing Drug Testing with Lab-Grown Human Muscles
Myomaker Bio is at the forefront of a new era in drug development. The company has developed human muscle organs and tissues that closely mimic the behavior of real muscles in the human body. By using these lab-grown muscles to test drugs, Myomaker Bio aims to speed up the creation of new medicines, particularly for rare diseases, and more accurately predict how drugs will perform in real patients before moving to clinical trials.
This innovative approach not only promises to accelerate the drug development process but also has the potential to significantly reduce the reliance on animal testing. Animal models, while commonly used, often fail to accurately predict human responses to drugs. Myomaker Bio’s human muscle platforms are designed to bridge this gap, offering a more reliable and ethical alternative.
Expert Team and Cutting-Edge Technology
The team behind Myomaker Bio comprises world-leading scientists and researchers in the field of muscle biology. Their combined expertise, built on more than 50 years of research, has led to the development of this groundbreaking technology. The founding team has secured over £37 million in R&D funding and published more than 100 peer-reviewed papers, underscoring their authority and innovation in the field.
Professor Mark Lewis, CEO of Myomaker Bio, expressed his excitement about the investment, stating, “It is extremely satisfying to see this outcome after many years of work in this area alongside our incredible team. For our investors to believe in us and our technologies is humbling and gratifying.” He emphasized the challenges in current drug development, noting that it remains slow, expensive, and heavily dependent on animal testing, which doesn’t always predict human outcomes.
Investment to Drive Growth and Impact
The £325,000 investment from SFC Capital will be instrumental in scaling Myomaker Bio’s technology and expanding its impact. The funding will be used to expand the scientific team, scale production of muscle models, and accelerate commercial partnerships. This financial boost will enable Myomaker Bio to bring its innovative solutions to market more quickly, potentially transforming the pharmaceutical industry.
Adam Beveridge, Principal at SFC Capital, highlighted the cutting-edge nature of Myomaker Bio’s work, stating, “The work that Myomaker Bio is doing is at the cutting edge of biology and technology development, and we’re proud to be able to support this exciting spinout business with £325k of pre-seed funding.”
Loughborough University’s Commitment to Innovation
This investment is a testament to Loughborough University’s strong innovation ecosystem. Professor Dan Parsons, Loughborough University’s Pro Vice-Chancellor for Research and Innovation, expressed his enthusiasm for the development, saying, “This is an exciting moment for Myomaker Bio and for Loughborough University’s innovation ecosystem. The team’s pioneering work in engineered human muscle systems is opening entirely new possibilities for safer, faster, and more human-relevant drug discovery.”
The success of Myomaker Bio underscores the university’s commitment to translating cutting-edge research into real-world impact. By supporting spin-out companies like Myomaker Bio, Loughborough University is playing a crucial role in driving innovation and addressing some of the most pressing challenges in healthcare and drug development.
The Future of Drug Testing
As Myomaker Bio moves forward with its expanded capabilities, the pharmaceutical industry may be on the cusp of a significant transformation. The use of lab-grown human muscles for drug testing could lead to faster, more accurate, and more ethical drug development processes. This could result in new treatments reaching patients more quickly, particularly for rare diseases where traditional drug development methods have often fallen short.
Moreover, the reduction in animal testing aligns with growing ethical concerns and regulatory pressures to find alternatives to animal models in scientific research. Myomaker Bio’s technology could play a pivotal role in addressing these concerns while improving the efficiency and effectiveness of drug development.
As Myomaker Bio continues to grow and refine its technology, it will be exciting to see how this innovation shapes the future of drug testing and development. The investment from SFC Capital marks a significant step forward in this journey, bringing us closer to a new era of pharmaceutical research and development.
